We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Evaluation of Efficacy of <sup>99m</sup>Tc-Ethambutol in Tubercular Lesion Imaging.
- Authors
Singh, Namrata; Bhatnagar, A.
- Abstract
Purpose. The aim of this work was to develop specific radiopharmaceutical and to evaluate its efficacy in human to detect and locate the tubercular lesion. Materials and Methods. 99mTc-Ethambutol (EMB) was produced by direct labeling method. In vitro and in vivo biological studies and animal experiments were done. Phase I Clinical trial was performed. As per plan, 2 normal human subjects for biodistribution studies and fourteen patients (8 males and 6 females; age range of 25-50, with one patient aged 12 years as an exception) were chosen for clinical trial. Whole body scan and spots were acquired at 1 hour and 4 hour. Angiography, blood pool, and 24-hours spot images of the infected areas were also acquired. Result. Radiolabeling yielded >85% of labeled complex. In vitro and in vivo biological studies and animal experiments indicated 99mTc-EMB as a specific tuberculosis imaging agent. The biodistribution study in normal human subjects suggested stability of 99mTc-EMB, with main excretory pathways being renal and hepatobiliary, which appeared to be similar to the known behavior of unlabeled EMB. No adverse reactions were observed. 99mTc- EMB got localized in pulmonary and bone tubercular lesions. Scintigrams of 99mTc-EMB and 99mTc-Ciprofloxacin were compared at different time intervals. Conclusion. The present study states that developed 99mTc-EMB has high potential to qualify as a specific tuberculosis imaging radiopharmaceutical and is safe for human use.
- Subjects
RADIOPHARMACEUTICALS; TUBERCULOSIS diagnosis; RADIOSCOPIC diagnosis; TUBERCULARIALES; RADIOLABELING; BIOMARKERS; CLINICAL trials; CIPROFLOXACIN
- Publication
Tuberculosis Research & Treatment, 2010, p1
- ISSN
2090-150X
- Publication type
Article
- DOI
10.1155/2010/618051